EUCTR2014-001441-24-AT进行中（未招募）1 期
Short-term effect of SGLT 2-inhibitor dapagliflozin on postprandial glucose excursion and insulin sensitivity in type 1 diabetic patients.
Medical University Innsbruck0 个研究点目标入组 12 人开始时间: 2014年8月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •-Typ 1 Diabetes Mellitus (duration at least 5 years)
- •-C-Peptid < 0.2µg/l
- •-aged 18 to 60 years
- •-Body Mass Index 20 – 25 kg/m2
- •-absence of clinically relevant ketonuria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 12
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-insufficient venous conditions on both forearms and cubita
- •-renal or hepatic insuffiency (including presence of mikroalbuminuria and determination of albumin/creatinin-ratio)
- •-History of malignant disease
- •-concomitant medicaion/ substances that may influence postprandial glucose excursion and/or fasting glucose-homeostasis within 3 months prior to study entry
- •-alcoholabuse and/or drugabuse, nikotinconsumption > 5 cigarettes per day
- •-brittle-diabetes
- •-history of severe hypoglycemia, defined as hypoglycemia the need for forein assistance independent of the effectively measured blood glucose concentration within 12 months prior to study entry
- •-any medical/individual condition that may jeopardize patients safety while participating in the study
研究者
相似试验
招募中
不适用
ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000026042Kurume University School of Medicine300
尚未招募
不适用
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
进行中（未招募）
不适用
Impact of treatment with Dapagliflozin in type 1 diabetic patientsType 1 diabetesEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
已完成
4 期
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial InfarctionMyocardial InfarctionDiabete Type 2Glucose IntoleranceNCT05050500Qingdao Central Hospital143
已完成
2 期
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424DiabetesNL-OMON48616Radboud Universitair Medisch Centrum15